Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C26H36N2O4.ClH |
| Molecular Weight | 477.036 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC=C(CCNCCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
InChI
InChIKey=OEAFTRIDBHSJDC-UHFFFAOYSA-N
InChI=1S/C26H36N2O4.ClH/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5;/h8-11,16-17,19,28H,7,12-15H2,1-6H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C26H36N2O4 |
| Molecular Weight | 440.575 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. | 2010-12-14 |
|
| Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats. | 2010-04 |
|
| Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. | 2010-03 |
|
| Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. | 2010-02-20 |
|
| Absorption barriers in the rat intestinal mucosa: 2. Application of physiologically based mathematical models to quantify mechanisms of drug permeation and metabolism. | 2010-02 |
|
| Absorption barriers in the rat intestinal mucosa: 1. Application of an in situ perfusion model to simultaneously assess drug permeation and metabolism. | 2010-02 |
|
| Absorption barriers in the rat intestinal mucosa. 3: Effects of polyethoxylated solubilizing agents on drug permeation and metabolism. | 2010-02 |
|
| Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. | 2010-01 |
|
| Different effects of ketoconazole on the stereoselective first-pass metabolism of R/S-verapamil in the intestine and the liver: important for the mechanistic understanding of first-pass drug-drug interactions. | 2009-11 |
|
| Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin. | 2009-10 |
|
| Clinically important interaction between tedisamil and verapamil. | 2009-05 |
|
| Intravenous fat emulsion therapy for intentional sustained-release verapamil overdose. | 2009-05 |
|
| Drug-drug interaction studies in preclinical species: should metabolite(s) kinetics be studied? | 2009-03 |
|
| Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. | 2009-03 |
|
| Stereoselective first-pass metabolism of verapamil in the small intestine and liver in rats. | 2008-10 |
|
| Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. | 2008-09 |
|
| Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. | 2008-05 |
|
| Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. | 2008-05 |
|
| Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. | 2008-04 |
|
| Dietary salt does not influence the disposition of verapamil enantiomers in relation to efflux transporter ABCB1 genetic polymorphism in healthy Korean subjects. | 2008-04 |
|
| Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers. | 2008-01 |
|
| Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. | 2007-12-21 |
|
| Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). | 2007-09 |
|
| Comparison of sub-2-microm particle columns for fast metabolite ID. | 2007-05 |
|
| Simultaneous determination of ten antiarrhythic drugs and a metabolite in human plasma by liquid chromatography--tandem mass spectrometry. | 2007-03-01 |
|
| Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination. | 2007 |
|
| The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. | 2006-10 |
|
| Chiral capillary electrophoretic analysis of verapamil metabolism by cytochrome P450 3A4. | 2006-07-07 |
|
| Development of an in vitro rat intestine segmental perfusion model to investigate permeability and predict oral fraction absorbed. | 2006-07 |
|
| The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. | 2006-03 |
|
| Effect of naringin pretreatment on bioavailability of verapamil in rabbits. | 2006-01 |
|
| Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. | 2005-10 |
|
| Kinetic study of CYP3A4 activity on verapamil by capillary electrophoresis. | 2005-09-15 |
|
| Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. | 2005-05 |
|
| Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. | 2005-04 |
|
| Sensitive determination of clarithromycin in human plasma by high-performance liquid chromatography with spectrophotometric detection. | 2005-03-25 |
|
| Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). | 2005-03 |
|
| Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. | 2005-02 |
|
| The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits. | 2004-12 |
|
| Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatography-tandem mass spectrometry. | 2004-05-25 |
|
| St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. | 2004-04 |
|
| Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. | 2004-03 |
|
| Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. | 2004-02 |
|
| HPLC/MS findings in a fatality involving sustained-release verapamil. | 2003-09 |
|
| Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents. | 2003-08 |
|
| Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells. | 2003-07 |
|
| Verapamil: identification of novel metabolites in cultures of primary human hepatocytes and human urine by LC-MS(n) and LC-NMR. | 2003-06 |
|
| Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers. | 2003-05 |
|
| Demonstration of direct bioanalysis of drugs in plasma using nanoelectrospray infusion from a silicon chip coupled with tandem mass spectrometry. | 2003-02-15 |
|
| An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. | 2002 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 17:21:06 GMT 2025
by
admin
on
Wed Apr 02 17:21:06 GMT 2025
|
| Record UNII |
MX5JX4YHL8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MX5JX4YHL8
Created by
admin on Wed Apr 02 17:21:06 GMT 2025 , Edited by admin on Wed Apr 02 17:21:06 GMT 2025
|
PRIMARY | |||
|
DTXSID40987149
Created by
admin on Wed Apr 02 17:21:06 GMT 2025 , Edited by admin on Wed Apr 02 17:21:06 GMT 2025
|
PRIMARY | |||
|
155002
Created by
admin on Wed Apr 02 17:21:06 GMT 2025 , Edited by admin on Wed Apr 02 17:21:06 GMT 2025
|
PRIMARY | |||
|
67812-42-4
Created by
admin on Wed Apr 02 17:21:06 GMT 2025 , Edited by admin on Wed Apr 02 17:21:06 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
